Onconetix (Nasdaq: ONCO) is acquiring Realbotix LLC in an all-stock share exchange and highlighted Realbotix’s April 8, 2026 delivery of the first Vinci-equipped humanoid robot to Ericsson. Vinci is a patented AI vision system that recognizes returning users, recalls conversations, and tracks engagement for data collection.
The combined company is expected to trade on Nasdaq after closing, anticipated in the second half of 2026, subject to shareholder and regulatory approvals.
Loading…
Loading translation…
Positive
Definitive all-stock share exchange to acquire 100% of Realbotix LLC
First Vinci-equipped robot delivered to Ericsson (April 8, 2026)
Vinci enables identity, behavioral, emotional, and engagement analytics for clinical data
Negative
Closing is subject to Onconetix shareholder and regulatory approvals, creating timing uncertainty
Transaction is an all-stock deal, which will change shareholder mix though dilution details were not provided
+79.65%
Since News
+88.1%
Peak in 14 min
$2.02
Last Price
$1.10
$2.24
Day Range
+$347K
Valuation Impact
$783,007
Market Cap
2.1x
Rel. Volume
Following this news, ONCO has gained 79.65%, reflecting a significant positive market reaction.
Argus tracked a peak move of +88.1% during the session.
Our momentum scanner has triggered 28 alerts so far, indicating elevated trading interest and price volatility.
The stock is currently trading at $2.02.
This price movement has added approximately $347K to the company’s valuation.
Trading volume is elevated at 2.1x the average, suggesting notable buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Equity interests acquired
100% of equity interests
Planned acquisition of Realbotix LLC
Expected closing window
Second half of 2026
Anticipated close of Realbotix acquisition and combined Nasdaq listing
Reverse stock split ratio
1-for-5
Reverse split effective March 25, 2026
Shares pre-split
3,464,686 shares
Common shares outstanding before 1-for-5 reverse split
Shares post-split
692,927 shares
Common shares outstanding after 1-for-5 reverse split
Record date shares
3,473,352 shares
Common shares outstanding as of March 13, 2026
CEO base salary
$21,700 per month
David White employment agreement
Short interest
41.18%
Reported short interest as percent of float
$1.1300
Last Close
Volume
Volume 465,320 vs 20-day average 3,986,904 (relative volume 0.12x) shows muted trading ahead of this AI update.
low
Technical
Shares at $1.13 are trading below the 200-day MA of $12.09, near the 52-week low of $1.10 and far from the $74.29 high.
ONCO was down 12.4% pre-release while sector peers showed mixed moves: APVO +3.13%, OGEN -2.6%, QNRX -7.85%, XBIO -7.29%, SXTP -1.63%. Momentum data show 4 peers trending down, indicating broader biotech pressure overlapping with company-specific dynamics.
Date
Event
Sentiment
Move
Catalyst
Apr 02
AI delivery update
Positive
-18.9%
Realbotix expected delivery of 19 humanoid robots across Mar–May 2026.
Pattern Detected
Recent AI-tagged news tied to the Realbotix transaction coincided with a negative price reaction despite operational updates.
Recent Company History
This announcement continues a series of communications around Onconetix’s pending all-stock acquisition of Realbotix LLC and its AI humanoid robotics platform. On Feb 12, 2026, the company disclosed that Realbotix Parent could own 75–90% of fully diluted shares post-close. Subsequent updates included a 1-for-5 reverse stock split effective Mar 25, 2026 and multiple 425 filings summarizing Realbotix milestones. The prior AI-tagged delivery update on Apr 2, 2026 saw a -18.94% move, suggesting past AI news did not prevent selling pressure.
-18.9%
Average Historical Move
AI
In the past, ONCO’s AI-tagged Realbotix update on Apr 2, 2026 triggered a -18.94% move, showing that prior AI milestones around this acquisition coincided with selling pressure.
AI-tagged news has tracked Realbotix’s commercialization steps, from humanoid robot delivery schedules to specific deployments and technical capabilities integrated into the pending acquisition.
The stock is surging +79.7% following this news. A strong positive reaction aligns with the strategic shift toward AI-enabled humanoid robotics, as highlighted by Realbotix’s Vinci vision system and Ericsson deployment. Prior AI-tagged news on Apr 2, 2026 coincided with a -18.94% move, so a future rally would contrast with that pattern. Investors would need to weigh concentration of control post-deal and past reverse-split actions when assessing how durable any strength might be.
all-stock transaction
financial
“in an all-stock transaction. The combined company is expected to trade”
An all-stock transaction is a deal where one company acquires another using only its own shares instead of cash or other assets. For investors, this means exchanging ownership stakes rather than cash, which can affect the value and control of the companies involved. It often signals a focus on growth and can influence the stock prices of both companies.
definitive share exchange agreement
financial
“Onconetix entered into a definitive share exchange agreement to acquire”
A definitive share exchange agreement is the final, signed contract that sets the exact terms for one company to buy another by swapping shares rather than cash. It spells out how many new shares each owner receives, the conditions that must be met before the deal closes, and who controls the combined business — like a detailed recipe agreed by both chefs. For investors, it matters because it fixes ownership stakes, potential dilution, and the timetable and risks for completing the transaction.
reverse stock split
financial
“announces 1-for-5 reverse stock split effective 12:01 a.m. ET”
A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.
Registration Statement on Form S-4
regulatory
“states it will file a Registration Statement on Form S-4 to register”
A registration statement on Form S-4 is a formal filing with the U.S. Securities and Exchange Commission used when a company issues shares or other securities as part of a merger, acquisition, exchange offer or similar corporate deal. It bundles the transaction terms, financial statements, risk factors and shareholder vote materials so investors can assess the deal; think of it as a detailed prospectus or buyer’s packet that explains what you would own and how the deal could change your stake.
regulatory approvals
regulatory
“subject to Onconetix shareholder approval, required regulatory approvals, and other”
Regulatory approvals are official permissions from government agencies that a company needs before launching a new product, service, or business activity. They matter because without this approval, the company might not be allowed to operate legally or sell its products, similar to how a driver needs a license to legally drive a car.
clinical trials
medical
“Engagement analytics over time (clinical trials and data comparison).”
Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company’s future revenue, valuation and risk profile—think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.
AI-generated analysis. Not financial advice.
04/09/2026 – 07:30 AM
Vinci Enables Realbotix Robots to Recognize People, Recall Conversations, and Track Engagement; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp.
CINCINNATI, Ohio, April 09, 2026 (GLOBE NEWSWIRE) — Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC (“Realbotix”), the target of Onconetix’s previously announced pending acquisition.
On April 8, 2026, Realbotix announced that it has delivered its first Vinci-equipped humanoid robot to Ericsson. Vinci is a patented AI vision system that allows the robot to recognize returning users, recall previous conversations, and track engagement.
Vinci, Realbotix’s AI vision and eye tracking technology, incorporates in-eye cameras that provide real-time environmental awareness. With the ability to maintain eye contact, Vinci robots can recognize people they have previously interacted with, recall prior conversations, and continue them. Vinci can be added to any Realbotix robot model.
Vinci-enabled robots facilitate AI data collection from the humans they interact with, including the following:
Identity layer (who is interacting);Behavioral tracking (what they are doing);Emotional signal capture (how they respond and are feeling); andEngagement analytics over time (clinical trials and data comparison).
As previously announced on February 12, 2026, Onconetix entered into a definitive share exchange agreement to acquire 100% of the issued and outstanding equity interests of Realbotix LLC, a wholly-owned subsidiary of Realbotix Corp., in an all-stock transaction. The combined company is expected to trade on Nasdaq following closing, which is anticipated to occur in the second half of 2026, subject to Onconetix shareholder approval, required regulatory approvals, and other closing conditions.
This communication includes information regarding Realbotix, a company that Onconetix has agreed to acquire, and is being provided for informational purposes only. Investors are cautioned not to place undue reliance on forward-looking or projected information.
About Onconetix, Inc.
Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative oncology solutions. Onconetix owns Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the IVDR, which it anticipates will be marketed in the U.S. as a lab developed test through its license agreement with Labcorp. For more information, visit www.onconetix.com.
About Realbotix LLC
Realbotix LLC is a wholly-owned subsidiary of Realbotix Corp. (TSX-V: XBOT; Frankfurt: 76M0.F; OTC: XBOTF) and the target of Onconetix’s pending acquisition. Realbotix LLC develops AI-powered humanoid robots designed for human interaction across enterprise and consumer environments. Manufactured in the United States, Realbotix’s patented AI and robotics technologies enable lifelike expressions, motion, vision, and social engagement. For more information, visit www.realbotix.ai.
Additional Information and Where to Find It
In connection with the proposed transaction between Realbotix and Onconetix, Onconetix intends to file with the SEC a Registration Statement on Form S-4 (the “Registration Statement”) to register the common stock to be issued by Onconetix in connection with the proposed transaction. The Registration Statement will include a proxy statement of Onconetix and a prospectus of Onconetix (the “Proxy Statement/Prospectus”), and each of Realbotix and Onconetix may file with the SEC other relevant documents concerning the proposed transaction. After the Registration Statement is declared effective, the definitive Proxy Statement/Prospectus will be sent to the stockholders of Onconetix to seek their approval of the proposed transaction. This is not a substitute for the Registration Statement, the Proxy Statement/Prospectus or any other relevant documents that Realbotix or Onconetix has filed or will file with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS OF ONCONETIX ARE URGED TO CAREFULLY AND ENTIRELY READ THE REGISTRATION STATEMENT AND PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT REALBOTIX, ONCONETIX, THE PROPOSED TRANSACTION, AND RELATED MATTERS.
A copy of the Registration Statement, Proxy Statement/Prospectus, as well as other relevant documents filed by Realbotix and Onconetix with the SEC, may be obtained free of charge, when they become available, at the SEC’s website at www.sec.gov. The information on Realbotix or Onconetix’s respective websites is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.
Participants in the Solicitation
Realbotix, Onconetix and certain of their respective directors, executive officers, and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Onconetix, their ownership of Onconetix common stock, and Onconetix’s transactions with related persons is set forth in the 10-K, as filed with the SEC on March 13, 2026, and other documents that may be filed from time to time with the SEC. Additional information about the directors and executive officers of Realbotix and Onconetix and other persons who may be deemed to be participants in the solicitation of stockholders of Onconetix in connection with the proposed transaction and a description of their direct and indirect interests will be included in the Proxy Statement/Prospectus related to the proposed transaction or other relevant materials, which will be filed with the SEC. These documents may be obtained free of charge, when they become available, at the SEC’s website at www.sec.gov and from Onconetix using the sources indicated above.
No Offer or Solicitation
This communication is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or sell any securities or the solicitation of any proxy, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or in a transaction exempt from the registration requirements of the Securities Act.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements (including, without limitation, the anticipated benefits and opportunities that may be generated by the proposed transaction described herein) are based on Onconetix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the occurrence of any event, change, or other circumstances that could give rise to the right of one or both of the parties to terminate the share exchange agreement; the possibility that the proposed transaction does not close when expected or at all because the conditions to closing are not satisfied on a timely basis or at all, including the failure to timely obtain stockholder approval for the proposed transaction from Onconetix’s stockholders, if at all; risks related to Onconetix’s continued listing on Nasdaq until closing of the proposed transaction; the outcome of any legal proceedings that may be instituted against Realbotix, Onconetix, or the combined company; the possibility that the anticipated benefits of the proposed transaction are not realized when expected or at all; the possibility that the vision, goals, and trajectory of the combined company are not timely achieved or realized or achieved or realized at all; the possibility that the proposed transaction may be more expensive or take longer to complete than anticipated, including as a result of unexpected factors or events; the diversion of management’s attention from ongoing business operations and opportunities; changes in Onconetix’s stock price before closing; and other factors that may affect future results of Realbotix, Onconetix, or the combined company. Onconetix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Onconetix’s Annual Report on Form 10-K filed with the SEC on March 13, 2026 (the “10-K”) and periodic reports filed with the SEC on or after the date thereof. All of Onconetix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Investor and Media Contact:
Onconetix, Inc.
201 E. Fifth Street, Suite 1900
Cincinnati, OH 45202
Phone: (513) 620-4101
Email: investors@onconetix.com
FAQ
What did Onconetix announce about acquiring Realbotix LLC (ONCO) on April 9, 2026?
Onconetix announced a definitive all-stock share exchange to acquire 100% of Realbotix LLC. According to Onconetix, the transaction covers all issued and outstanding equity and is expected to close in the second half of 2026 subject to approvals.
What is Vinci and what did Realbotix deliver to Ericsson on April 8, 2026?
Vinci is a patented AI vision system that enables recognition, recall, and engagement tracking. According to Realbotix, the company delivered its first Vinci-equipped humanoid robot to Ericsson on April 8, 2026 for real-time eye-tracking and interaction.
How could Vinci-enabled robots support clinical trials for Onconetix (ONCO)?
Vinci-enabled robots collect identity, behavioral, emotional signals, and engagement analytics over time for clinical comparison. According to the companies, this allows standardized data capture from human interactions useful for trial endpoints and longitudinal analysis.
When is the Onconetix and Realbotix deal expected to close and trade on Nasdaq?
The combined company is expected to trade on Nasdaq following closing, anticipated in the second half of 2026. According to Onconetix, closing depends on shareholder approval, required regulatory approvals, and other customary closing conditions.